Page 16 - Cost Plus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.

With new untested service providers attempting to disrupt the industry, here’s what we think of CVS stock.

Our adventurous daily links: cat flips, dinosaur tracks, forgetting, moar variant worried, China wobblea, ECOWAS saddles up, F-16s to Ukraine, Lukashenko interview, "moderate Syrians"' hung out to dry, CA v. math, "dual sovereignity" minefield, no AI art copyright, inflation, Musk Twitter self-sabotage?

Blue Shield of California is cutting many of its ties with CVS Caremark (though not all) and adding four additional partners for its prescription drug benefits. These partners include Mark Cuban Cost Plus Drug Company and Amazon Pharmacy. The changes are needed to disrupt the current broken system, said Salina Wong, senior director of clinical pharmacy programs at Blue Shield of California.

The nonprofit health insurer, with 4.8 million members, expects the move to the low-cost pharmacies will provide $500 million in annual savings on drug costs.